Speech-Language Pathologists in Parkville, MO Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Jessica Ann Older Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15143 N Cherry Ct, Parkville, MO 64152 Phone: 217-276-5377

Samantha Beck, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5727 Thousand Oaks Dr, Parkville, MO 64152 Phone: 510-936-2386

Starr Therapies Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5856 S National Dr, Parkville, MO 64152 Phone: 816-719-1554

Mrs. Betsy Anne Sylvester, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6533 Nw Melody Ct, Parkville, MO 64152 Phone: 816-682-8650

Peptalk Speech Therapy Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5727 Thousand Oaks Dr, Parkville, MO 64152 Phone: 510-936-2386

News Archive

New procedure rapidly induces nerve regeneration

American scientists believe a new procedure to repair severed nerves could result in patients recovering in days or weeks, rather than months or years. The team used a cellular mechanism similar to that used by many invertebrates to repair damage to nerve axons. Their results are published today in the Journal of Neuroscience Research.

New treatment for children with autism to be unveiled at Queen's University Belfast

A new treatment for children with autism, which has the potential to significantly improve their learning and academic skills, will be unveiled at Queen's University Belfast today.

Paralysis from a stroke: Rare nerve transfer improves mobility

The Plastic Surgery Center today announced the successful results of a rare nerve transfer performed for the first known time on a stroke patient to reverse paralysis. Following the procedure, which was led by Dr. Andrew Elkwood, M.D., 47-year old Vincent Filipini is now able to lift, move and bend his once paralyzed arm. Mr. Filipini continues to show improvement in his mobility.

ODAC calls for randomized study of Vion's Onrigin injection for treatment of the elderly AML patients

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).

Researchers explain molecular mechanism that induces HER2+ tumours to ignore cell signals

About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.

Read more Medical News

› Verified 2 days ago